Predicting Immunotherapy Response for Liver Cancer
Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 350 (estimated)
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Other
This trial is looking for people with liver cancer who have been treated at Wuhan Union Hospital. Participants will provide imaging data to help predict how well they might respond to immunotherapy.
You may be able to join if
- I am older than 18 years
- I have been treated for liver cancer
- I have at least one CT or MR scan before treatment
- I have had a tissue biopsy that confirmed my diagnosis
You may not be able to join if
- I have poor image quality from my scans
- I have incomplete clinical data or lost follow-up
- I have another type of cancer besides liver cancer
- I have an unclear diagnosis
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityCT imaging data and MR imaging data from liver cancer (hepatocellular carcinoma) patients prior to the initiation of immunotherapy (and possibly also after treatment) will be collected. The processing pipeline includes automatic tumor segmentation, radiomics feature extraction, feature selection, and construction of a classification model.
Loading trial locations…